Effects of a Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin on Pancreas in Obese Diabetic Mice - PubMed
6 hours ago
- #Pancreas
- #Dapagliflozin
- #Diabetes
- Dapagliflozin, an SGLT2 inhibitor, was studied for its effects on the pancreas in obese diabetic mice.
- The study found that dapagliflozin increased blood insulin levels and improved hyperglycemia.
- Histological analysis showed increased islet areas and improved islet irregularity and fibrosis in a dose-dependent manner.
- Immunostaining revealed a dose-dependent increase in β-cell positive areas and a decrease in the α-cell/β-cell area ratio.
- Dapagliflozin suppressed the expression of CD44, an inflammation- and fibrosis-related factor, around pancreatic islets.
- The study suggests that long-term dapagliflozin administration may protect the pancreas in type 2 diabetes.